Coverage at a glance
| Indication | Coverage |
|---|---|
| Type 2 diabetes | Covered with prior authorization |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
Coverage by indication
| Step therapy |
What the prior authorization needs:
- Rybelsus is a preferred GLP-1 agent on the commercial medical necessity policy
- Type 2 diabetes confirmed by an A1C of 6.5% or higher, a fasting blood glucose of 126 mg/dL or higher, or an oral glucose tolerance test of 200 mg/dL or higher
- Documented inadequate response, intolerable side effect, or contraindication to metformin, OR a need for combination therapy with an A1C of 7.5% or higher
- Not used in combination with another GLP-1 receptor agonist
- Dose does not exceed the FDA-label maximum
- Prior authorization required; approval lasts one year
Source: Glucagon-Like Peptide-1 (GLP-1) Agents, Commercial: BSC Medication Policy to Determine Medical Necessity (effective 5/3/2023). policy. Verified August 28, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does Blue Shield of California cover Rybelsus?
Blue Shield of California covers Rybelsus (oral semaglutide) for type 2 diabetes with prior authorization. The commercial GLP-1 medical necessity policy lists Rybelsus as a preferred GLP-1 agent and requires a confirmed type 2 diabetes diagnosis (an A1C of 6.5% or higher) plus step therapy: an inadequate response, intolerable side effect, or contraindication to metformin, unless the member needs combination therapy at an A1C of 7.5% or higher. Rybelsus is not covered for weight loss, because it is FDA-approved for type 2 diabetes only. Wegovy is the semaglutide product indicated for weight loss. This reflects the published policy verified August 2026.
What does Blue Shield of California require to approve Rybelsus?
For type 2 diabetes: true
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
